ReviewInternational journal of clinical oncology2019
Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.
Review in International journal of clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Identifying actionable genetic mutations and microsatellite instability in liquid biopsy of colorectal cancer.Journal, genetic engineering & biotechnology · 2025Article
- Maximizing the clinical utility and performance of cytology samples for comprehensive genetic profiling.Nature communications · 2025Article
- Article
- Genetic variant classification by predicted protein structure: A case study on IRF6.Computational and structural biotechnology journal · 2024Article
- Article
- Validation and Implementation of a Somatic-Only Tumor Exome for Routine Clinical Application.The Journal of molecular diagnostics : JMD · 2024Article
- Article
- Paired comparison of the analytical performance between the Oncomine™ Comprehensive Assay v3 and whole-exome sequencing of ovarian cancer tissue.Molecular biology reports · 2024Article
- SLC31A1 Identifying a Novel Biomarker with Potential Prognostic and Immunotherapeutic Potential in Pan-Cancer.Biomedicines · 2023Article
- Noncoding RNAs in tumorigenesis and tumor therapy.Fundamental research · 2023Review
- Personalized Precision Medicine for Health Care Professionals: Development of a Competency Framework.JMIR medical education · 2023Article
- Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA.Therapeutic advances in medical oncology · 2023Review
- Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches.Molecules (Basel, Switzerland) · 2022Review
- Fecal gene detection based on next generation sequencing for colorectal cancer diagnosis.World journal of gastroenterology · 2022Article
- Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer.Current oncology (Toronto, Ont.) · 2022Article
- Applications and Biocompatibility of Mesoporous Silica Nanocarriers in the Field of Medicine.Frontiers in pharmacology · 2022Review
- Validation of an NGS Panel Designed for Detection of Actionable Mutations in Tumors Common in Latin America.Journal of personalized medicine · 2021Article
- The Downregulation ofJournal of personalized medicine · 2021Article
- Integrated magneto-electrophoresis microfluidic chip purification on library preparation device for preimplantation genetic testing for aneuploidy detection.RSC advances · 2021Article
- Molecular Testing on Cytology for Gene Fusion Detection.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Numerous technical and functional advances in next-generation sequencing (NGS) have led to the adoption of this technique in conventional clinical practice. Recently, large-scale genomic research and NGS technological innovation have revealed many more details of somatic and germline mutations in solid tumors. This development is allowing for the classification of tumor type sub-categories based on genetic alterations in solid tumors, and based on this information, new drugs and targeted therapies are being administered to patients. This has largely been facilitated by gene panel testing, which allows for a better understanding of the genetic basis for an individual's response to therapy. NGS-based comprehensive gene panel testing is a clinically useful approach to investigate genomic mechanisms, including therapy-related signaling pathways, microsatellite instability, hypermutated phenotypes, and tumor mutation burden. In this review, we describe the concept of precision medicine in solid tumors using NGS-based comprehensive gene panel testing, as well as the importance of quality control of tissue sample handling in routine NGS-based genomic testing, and we discuss issues for the future adoption of this technique in Japan.
Indexed as
Identifiers
30515675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.